FMS

Fresenius Medical Care AG

Fresenius Medical Care AG is classed by the SEC under Services-Misc Health & Allied Services, NEC (industry code 8090), based in Bad Homburg, DE. Its latest filed balance sheet shows total assets of $27 billion (its filed statements).

Usage business Services-Misc Health & Allied Services, NEC Bad Homburg, DE filings since 2005 8 of 9 filed, 1 estimated

Sector peers: PGNYDVAVMDSHC

5.2/10headline grade
vs its business-model standard

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8090, Services-Misc Health & Allied Services, NEC); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.2 out of ten, 8 of 9 metrics filed and 1 estimated: past 5.7 out of ten, present 4.9 out of ten, future 5.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 4.6 out of ten. +1.9% a year over 10 filed years; profitable in 10 of 10. 46th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 4.3 out of ten. Share count shrank 0.2% a year. 8% of cash flow returned. Insiders: 0 sales, 0 purchases. 43rd percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.1 out of ten. ROE 8%: 8¢ of profit per shareholder dollar. Leverage 54%: owes 54¢ per asset dollar. 51st percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 4.5 out of ten. bottom 45% of 10 in its family; net margin 6.1%. 45th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 20 of 100 (family median). 50th percentile among 9 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Room to expand (future): 4.0 out of ten. bottom 40% of 10 in its family for room to expand. 40th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 4.4 out of ten. bottom 44% of 10 in its family for growth drivers. 44th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 7.2 out of ten. top 28% of 10 in its family for expectations against reality. 72nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 20-F filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-10-07. Filings on record since 2005. Read from EDGAR 2026-10-12.

Who runs it

Renkewitsch, Olga (Head of Global Accounting and Controlling (Chief Accounting Officer). Exhibit 24 - Power of Attorney). 1 officer or director has filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.